메뉴 건너뛰기




Volumn 45, Issue 1, 2015, Pages 260-262

Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment

(14)  Roche, Nicolas a   Jebrak, Gilles b   Caillaud, Denis c   Deslée, Gaetan d   Brinchault, Graziella e   Chanez, Pascal f   Court Fortune, Isabelle g   Escamilla, Roger h   Nesme Meyer, Pascale i   Pinet, Christophe j   Carré, Philippe k   Paillasseur, Jean Louis l   Perez, Thierry m   Burgel, Pierre Régis a  


Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC AGENT; TIOTROPIUM BROMIDE; DELAYED RELEASE FORMULATION; MUSCARINIC RECEPTOR BLOCKING AGENT;

EID: 84920560776     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00131614     Document Type: Letter
Times cited : (3)

References (14)
  • 2
    • 79953166862 scopus 로고    scopus 로고
    • Tiotropium versus salmeterol for the prevention of exacerbations of COPD
    • Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-1103.
    • (2011) N Engl J Med , vol.364 , pp. 1093-1103
    • Vogelmeier, C.1    Hederer, B.2    Glaab, T.3
  • 3
    • 33847172367 scopus 로고    scopus 로고
    • Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    • Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
    • (2007) N Engl J Med , vol.356 , pp. 775-789
    • Calverley, P.M.1    Anderson, J.A.2    Celli, B.3
  • 4
    • 79953283384 scopus 로고    scopus 로고
    • Combination inhaled steroid and long-acting β2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
    • Karner C, Cates CJ. Combination inhaled steroid and long-acting β2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 3: CD008532.
    • (2011) Cochrane Database Syst Rev , vol.3 , pp. CD008532
    • Karner, C.1    Cates, C.J.2
  • 5
    • 84878922304 scopus 로고    scopus 로고
    • Guideline adherence in management of stable chronic obstructive pulmonary disease
    • Sharif R, Cuevas CR, Wang Y, et al. Guideline adherence in management of stable chronic obstructive pulmonary disease. Respir Med 2013; 107: 1046-1052.
    • (2013) Respir Med , vol.107 , pp. 1046-1052
    • Sharif, R.1    Cuevas, C.R.2    Wang, Y.3
  • 6
    • 84897405184 scopus 로고    scopus 로고
    • Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: A paradigm shift in GOLD 2011
    • Burgel PR, Deslée G, Jebrak G, et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Eur Respir J 2014; 43: 1201-1203.
    • (2014) Eur Respir J , vol.43 , pp. 1201-1203
    • Burgel, P.R.1    Deslée, G.2    Jebrak, G.3
  • 7
    • 79958816304 scopus 로고    scopus 로고
    • Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: A retrospective actuarial claims data analysis
    • Fitch K, Iwasaki K, Pyenson B, et al. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin 2011; 27: 1425-1429.
    • (2011) Curr Med Res Opin , vol.27 , pp. 1425-1429
    • Fitch, K.1    Iwasaki, K.2    Pyenson, B.3
  • 8
    • 84860767710 scopus 로고    scopus 로고
    • Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort
    • Jochmann A, Scherr A, Jochmann DC, et al. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. Swiss Med Wkly 2012; 142: w13567.
    • (2012) Swiss Med Wkly , vol.142 , pp. w13567
    • Jochmann, A.1    Scherr, A.2    Jochmann, D.C.3
  • 9
    • 84860304497 scopus 로고    scopus 로고
    • Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
    • Asche CV, Leader S, Plauschinat C, et al. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2012; 7: 201-209.
    • (2012) Int J Chron Obstruct Pulmon Dis , vol.7 , pp. 201-209
    • Asche, C.V.1    Leader, S.2    Plauschinat, C.3
  • 10
    • 84875820681 scopus 로고    scopus 로고
    • How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease
    • Antón E. How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease? Expert Rev Respir Med 2013; 7: 25-32.
    • (2013) Expert Rev Respir Med , vol.7 , pp. 25-32
    • Antón, E.1
  • 11
    • 84905639968 scopus 로고    scopus 로고
    • The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients
    • De Backer W, Vos W, Van Holsbeke C, et al. The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients. Eur Respir J 2014; 44: 527-529.
    • (2014) Eur Respir J , vol.44 , pp. 527-529
    • De Backer, W.1    Vos, W.2    Van Holsbeke, C.3
  • 12
    • 84905667274 scopus 로고    scopus 로고
    • Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease
    • Page C, Cazzola M. Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. Eur Respir J 2014; 44: 475-482.
    • (2014) Eur Respir J , vol.44 , pp. 475-482
    • Page, C.1    Cazzola, M.2
  • 13
    • 84895548677 scopus 로고    scopus 로고
    • A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
    • Agustí A, de Teresa L, De Backer W, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J 2014; 43: 763-772.
    • (2014) Eur Respir J , vol.43 , pp. 763-772
    • Agustí, A.1    De Teresa, L.2    De Backer, W.3
  • 14
    • 84879524095 scopus 로고    scopus 로고
    • Long-term macrolide treatment for chronic respiratory disease
    • Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 2013; 42: 239-251.
    • (2013) Eur Respir J , vol.42 , pp. 239-251
    • Spagnolo, P.1    Fabbri, L.M.2    Bush, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.